Antipsychotics

The death toll among Japanese citizens who have taken Johnson & Johnson's subsidiary Janssen's schizophrenia drug Xeplion has climbed to 21, from 17 on...

The FDA approved the prescribing and sale of a new hi-tech compliance-monitoring “antipsychotic” drug this week. A new chapter in human darkness has descended — one that is applauded by the alliance of control addicts that made it happen.

New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”

Over one third of people with bipolar diagnoses admitted to a Rhode Island hospital were on four or more psychiatric medications, says research published...

The Wunderink study has been discussed here in other blogs. In brief, using a randomized control design, Wunderink found that in adults diagnosed with a psychotic disorder continuous use of neuroleptics was associated with worse functional outcomes. Is this study relevant to those who do not experience psychosis?

No placebo controlled trials provide evidence of antipsychotics in first-episode psychosis.

Researchers examine how rapid discontinuation can mimic the relapse of mental health symptoms and confound psychiatric drug studies.

Out here in Minnesota, where the snow is gently falling, many of us are hunched over our computers, puzzling over a document just posted by the state Board of Social Work. It concerns the death of Dan Markingson (or as the document calls him, “Client #1”). Markingson, of course, was a young man under a commitment order who was coerced into a profitable Seroquel marketing study at the University of Minnesota over the objections of his mother, and whose condition spiraled downward until he committed suicide.

Members of the U.S. Food and Drug Administration’s Psychiatry Products division go on the defensive in a new article, responding to concerns about the agency’s approval of digital aripiprazole.

Back in 2006, when my son Franklin was in his late twenties and living in a group home in the Boston area, he refused to take Clozaril any more because of the required bi-weekly blood draws. His doctor prescribed Zyprexa as a substitute, and Frank suddenly began to gain weight ... a lot of weight. Later, I would learn that UCLA psychiatrist Dr. William Wirshing had said of Zyprexa prior to its 1996 approval by the FDA: “It is just un-stinkin’-believable. It is the best drug for gaining weight I’ve ever seen.” The doctor indicated that taking ten milligrams of the medication was equivalent to ingesting 1,500 extra calories per day. My outrage knew no bounds.

More than half of the prescriptions for antipsychotic drugs in the UK are being issued "off-label" to treat conditions other than those for which the drugs are approved, according to a large study published in the British Medical Journal Open. Researchers also found significantly higher levels of prescribing of the medications to poorer people.

Martin Harrow along with his colleagues T.H. Jobe and R. N. Faull has published another paper on the long term outcome of people who experienced a psychotic episode. Funded by a grant from the Foundation for Excellence in Mental Health Care, this paper adds to our knowledge of an extremely important and valuable study.

During a period of self-doubt, I chose to see a psychiatrist because I was engulfed in negative thoughts and couldn't find a direction in life. The slightest joys came only when I was high. Though my weed addiction was likely causing all of my symptoms, my psychiatrist’s response was to prescribe antipsychotics.

The recent research scandals out of the University of Minnesota’s Department of Psychiatry may be alarming, but they are not new. Back in the 1990s, when the university was working its way towards a crippling probation by the National Institutes of Health (for yet another episode of misconduct (this time in the Department of Surgery), the Department of Psychiatry hosted two spectacular cases of research wrongdoing, both of which resulted in faculty members being disqualified from conducting research by the FDA.

Researchers point to the risks of using antipsychotics with youth and caution against the practice.

On Monday, the US Supreme Court declined to hear Johnson and Johnson’s final appeal, forcing the company to pay $124 million for the deceptive marketing of the antipsychotic Risperdal. In 2011, South Carolina ordered the company to pay $327 million for pursuing “profits-at-all-costs” in its efforts to persuade doctors to prescribe their drug, but the fine was lowered to $136 million last year. The company had hoped to argue that the remaining penalties constituted an “excessive fine” and was supported by PhRMA, the Washington Legal Foundation, the Cato Institute and the Chamber of Commerce.

With increasing evidence that psychiatric drugs do more harm than good over the long term, the field of psychiatry often seems focused on sifting through the mounds of research data it has collected, eager to at last sit up and cry, here’s a shiny speck of gold! Our drugs do work! One recently published study on withdrawal of antipsychotics tells of long-term benefits. A second tells of long-term harm. Which one is convincing?

A review article and meta-analysis of 18 articles published in the journal of Psychological Medicine reported effects of vitamin and/or mineral supplements on psychiatric symptoms in people diagnosed with schizophrenia. The study provides evidence of the beneficial effects of taking certain vitamins and minerals for improving symptoms associated with schizophrenia.

In a featured article for Psychiatric Services, psychiatrists from Dartmouth raise the alarm on the increasing numbers of children prescribed dangerous antipsychotic drugs. Despite the fact that data on the safety of long-term use of these drugs in this vulnerable population “do not exist,” the rate of children and adolescents being prescribed antipsychotic drugs have continued to increase over the past fifteen years.

Researchers in Germany, China and Australia teamed up to find, through a meta-analysis of research pertaining to 1045 patients receiving antipsychotics, that augmentation with...

In this post for Better Health While Aging, Dr. Leslie Kernisan discusses the importance of making sure that older adults are taking the minimum amount...

Researchers recommend that healthcare professionals be vigilant regarding the signs of respiratory failure among patients with COPD who are receiving antipsychotics, especially during the initial treatment phase.

BPS releases report encouraging behavioral interventions for people with dementia, rather than antipsychotics

The researchers find that the drug effects for reducing psychosis are small and that treatment failure and severe side effects are common.

A new study offers radical solutions for improving the cardiovascular health of people with mental health diagnoses: reducing antipsychotic prescriptions..